Carillon Eagle Small Cap Growth Fund Q1 2025 Commentary
Source: SeekingAlpha
2025-05-28 12:16:00 ET
Summary
- Small-cap stocks experienced a broad drawdown in Q1 with the Russell 2000® Growth Index (down 11.12%) trailing the Russell 2000® Value Index (down 7.74%) by a notable margin.
- Equity markets endured a painful first quarter as uncertainty surrounding U.S. trade policy and its implications for economic growth and profits weighed heavily on investor sentiment.
- Despite the obvious headwinds facing the equity market, we are constructive on stocks at current levels.
Market Overview
Read the full article on Seeking Alpha
For further details see:
Carillon Eagle Small Cap Growth Fund Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
1.88% G/L:
$59.48 Last:
305,219 Volume:
$58.47 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
